Table III.
Characteristics of large-scale clinical-grade NK cell products expanded in G-Rex vessels.
| Validation 1, healthy donor | Validation 2, healthy donor | Clinical product, MM patient | Clinical product, healthy haplo-identical donor | |
|---|---|---|---|---|
| % viable cells (7-AAD−) | 72.4 | 86.4 | 82.9 | 90.8 |
| % CD3+ CD56− pre-T-cell depletion | 34.1 | 18.7 | 3.5 | 8.1 |
| % CD3+ CD56− post-T-cell depletion | 1 | 0.04 | n/a | 0.7 |
| % CD19+ | 0.56 | 0.56 | 1.98 | 1.24 |
| % CD14+ | 0.09 | 0.05 | 0.24 | 0.05 |